Effects of SCN1A Gene Polymorphisms on efficacy and safety of carbamazepine treatment on partial-onset seizures in Chinese Han Population

作     者：Bo-Ting Zhou1,2,Qiu-Hong Zhou3,Guo-Liang Li4,Jian Qu1,Ding Liu5,Xiao-Jing Xu1,Lan-Juan Zhao6,Hong-Hao Zhou1,Zhao-Qian Liu1(1Institute of Clinical Pharmacology,Hunan Key Laboratory of Pharmacogenetics,Central South University Xiang-Ya School of Medicine 2Department of Pharmacy,Xiang-Ya Hospital of Central South University,Changsha,Huan,China 3Department of Endocrinology,Xiang-Ya Hospital of Central South University,Changsha,Hunan,China 4Department of Neurology,Xiang-Ya Hospital of Central South University,Changsha,Hunan,China 5Department of Neurology,Third Xiang-Ya Hospital of Central South University,Changsha,Hunan,China 6Osteoporosis Research Center,Creighton University Medical Center,Omaha,NE,USA) 

会议名称：《传承与发展，创湖南省生理科学事业的新高——湖南省生理科学会2011年度学术年会》

会议日期：2011年

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

关 键 词：SCN1A,genetic polymorphism,carbamazepine,epilepsy 

摘      要：Aims In this study,for rs3812718 G/A and rs2298771 A/G polymorphisms of sodium channel α subunit type 1(SCN1A)gene,we investigated whether SCN1A polymorphisms impacted the efficacy and safety of carbamazepine(CBZ)in treating Chinese Han epileptic patients. Methods Three hundred fifty-seven epileptic patients were genotyped for